Evaluating Rosuvastatin 10 mg with Standard Treatment for Mild to Moderate Major Depressive Disorder in Adults Aged 20 to 45

What this Trial Is About

Researchers are evaluating the use of Rosuvastatin 10 mg to treat Major Depressive Disorder MDD in adults aged 20 to 45 years with mild to moderate depression. This randomized controlled trial aims to determine if Rosuvastatin lowers depression severity, measured by the Montgomery Asberg Depression Rating Scale MADRS, and to assess its safety. Participants must have a confirmed diagnosis of MDD and a MADRS score between 7 and 34. Participants will be assigned to one of two groups a control group receiving the standard depression treatment with Sertraline, and an interventional group receiving Sertraline plus Rosuvastatin 10 mg daily for 3 months. Serum cholesterol levels will be measured at the start and after 12 weeks. Medication adherence is monitored by pill counts during clinic visits every 4 weeks. During the study, participants will visit the clinic once every 4 weeks for assessments including depression severity using MADRS, side effect monitoring, and blood tests for cholesterol levels. The primary outcome is the change in depression severity after 12 weeks. The total participation duration is approximately 3 months, with data kept confidential and ethical oversight provided by the Ain Shams University research committee.

Efficacy of Statins Among Major Depressive Disorder